Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Cantrixil

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Lonza signs manufacturing agreement with Oasmia for ovarian cancer drug
    Lonza signs manufacturing agreement with Oasmia for ovarian cancer drug

    22 Mar 2022

    // S. Koltrowitz REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/lonza-signs-manufacturing-agreement-with-oasmia-ovarian-cancer-drug-2022-03-21/

    S. Koltrowitz REUTERS
    22 Mar 2022
    Share Share
    Oasmia acquires rights to cancer drug candidate Cantrixil in $44m deal
    Oasmia acquires rights to cancer drug candidate Cantrixil in $44m deal

    01 Mar 2021

    // PHARMAFILE

    http://www.pharmafile.com/news/571751/oasmia-acquires-rights-cancer-drug-candidate-cantrixil-44m-deal

    PHARMAFILE
    01 Mar 2021
    Share Share
    Kazia Licenses Cantrixil, a Clinical-stage Ovarian Cancer Drug, to Oasmia
    Kazia Licenses Cantrixil, a Clinical-stage Ovarian Cancer Drug, to Oasmia

    01 Mar 2021

    // PRNASIA

    https://en.prnasia.com/releases/apac/kazia-licenses-cantrixil-a-clinical-stage-first-in-class-ovarian-cancer-drug-candidate-to-oasmia-pharmacetical-ab-310003.shtml

    PRNASIA
    01 Mar 2021
    Share Share